The approval is the strongest challenge yet to Pfizer’s pneumococcal vaccine franchise, led by its 20-valent Prevnar 20 shot, which generated $6.4 billion in sales last year from use for ...

The CHMP’s recommendation was based on results from the late-stage STRIDE-3 trial, which compared Capvaxive to Pfizer’s 20-valent vaccine (PCV20) in adults who had not previously received a ...

It had a safety profile similar to Pfizer's market-leading Prevnar 20, which targets 20 common ... The company is also developing a 24-valent pneumococcal vaccine, VAX-24, which is in a phase ...

Among them are data from the phase III STRIDE-3 study, which evaluated Capvaxive compared to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults aged 18 years and above who had not ...

the serotypes covered by CAPVAXIVE are responsible for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate vaccine): Data were included for select countries based on EU ...

Apart from this franchise, its lead clinical candidate is VAX-24, a 24-valent pneumococcal conjugate ... s standard of care PCV20 vaccine on the existing 20 serotypes (and was statistically ...

Based on country-level data from the following four EU countries, the serotypes covered by Capvaxive are responsible for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent conjugate ...